Vision

Prof. Dan Peer’s work is in the interface of materials science, chemistry, molecular biology and immunology. He established a dynamic, multidisciplinary lab which focuses on developing targeted vehicles for cell specific delivery of drugs, including small molecules, proteins, DNA and RNA payloads. Prof. Peer has set a goal to translate academic discoveries into novel therapeutic modalities. With that, he founded the SPARK Tel Aviv initiative to accelerate cures via academic discoveries. Prof. Peer strives to develop the career of young students and encourage them to fulfil their ambitious and dreams.

Active Research
ERC project

LeukoTheranostics – Harnessing targeted nanotheranostics to reprogram activated leukocytes in inflammatory bowel disease

Read More »
About The Lab

The Peer lab is designing novel methodologies to manipulate cells’ function in vivo, using targeted, safe, lipid nanoparticles. They are utilizing nanotechnology tools to generate novel therapeutic strategies for inflammatory diseases and cancers. The lab is combining multidisciplinary approaches including immunology, cell and molecular biology, genetics, protein engineering, material sciences, nanotechnology and computational techniques for drug discovery. In addition, they are designing highly selective targeted nanocarriers able to reprogram cells in a discerning manner, with an ultimate goal to translate the findings into clinical settings.

 

About The Lab

The Peer lab is designing novel methodologies to manipulate cells’ function in vivo, using targeted, safe, lipid nanoparticles. They are utilizing nanotechnology tools to generate novel therapeutic strategies for inflammatory diseases and cancers. The lab is combining multidisciplinary approaches including immunology, cell and molecular biology, genetics, protein engineering, material sciences, nanotechnology and computational techniques for drug discovery. In addition, they are designing highly selective targeted nanocarriers able to reprogram cells in a discerning manner, with an ultimate goal to translate the findings into clinical settings.

 

Manuscripts
0
Citations
0
Patents
0
Wine bottles
0
Articles

Biontech sign license agreement to use novel set of lipids for improved MRNA delivery, developed at the Peer lab. 

December 2018